Harbin Pharmaceutical Group Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, wholesale, and retail of pharmaceuticals in China and internationally. The company offers pharmaceutical products for respiratory, chronic, digestive, blood and hematopoietic, anti-tumor and immunomodulatory, anti-inflammatory and analgesic, anti-virus and anti-infection, cerebrovascular, and cardiovascular diseases, as well as mineral and nutritional supplements, Chinese medicines, and antibiotics. It also provides calcium iron zinc oral solutions, zinc gluconate oral solutions, compound calcium gluconate oral solutions, Shuanghuanglian oral solutions, amoxicillin capsules, recombinant human erythropoietin injections, ibuprofen granules, iron vitamin B12 oral solutions, ceftriaxone sodium injections, pediatric acetaminophen granules, Jiananxi Vitapak nutrition packages, lacidipine tablets, roxatidine acetate hydrochloride for injections, and penicillin and cephalosporin antibiotic preparations. The company sells its products under the Harbin Pharmaceutical, Sanjing, Gaizhonggai, Hutong, and Shiyitang brands. It is also involved in culture, science and technology, passenger transport, food, property, security, and pharmaceutical investment services, as well as biology and health technology activities. Harbin Pharmaceutical Group Co., Ltd. was founded in 1991 and is based in Harbin, China.
Metrics to compare | 600664 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship600664PeersSector | |
---|---|---|---|---|
P/E Ratio | 15.0x | −9.6x | −0.5x | |
PEG Ratio | −6.41 | 0.53 | 0.00 | |
Price/Book | 1.8x | 2.2x | 2.6x | |
Price / LTM Sales | 0.6x | 3.6x | 3.0x | |
Upside (Analyst Target) | - | 22.3% | 56.3% | |
Fair Value Upside | Unlock | 5.2% | 10.0% | Unlock |